Table 1 Clinical characteristics of the study subjects.

Number

151

61

Gender (female/male)

145/6

58/3

Age (years)

54 (43.5–61)

50 (43–57)

Disease durations (years)

3 (1–6)

–

Dry mouth, n (%)

81 (53.6)

–

Dry eyes, n (%)

48 (31.8)

–

Extra-glandular manifestations

Articular involvement, n (%)

52 (34.4%)

–

Pulmonary involvement, n (%)

73 (48.3%)

–

ILD, n (%)

33 (21.9%)

–

Renal involvement, n (%)

13 (8.61%)

–

Cutaneous involvement, n (%)

20 (13.2%)

–

Neurological involvement, n (%)

18 (11.9%)

–

Hematological involvement, n (%)

39 (25.8%)

–

Malignant lymphoma, n (%)

1 (0.66%)

–

Treatment

 Prednisone (%)

58.9

–

 Chloroquine (%)

64.9

–

 Methotrexate (%)

4.63

–

 Cyclophosphamide (%)

3.31

–

 Mycophenolate mofetil (%)

15.23

–

 Cyclosporin A (%)

5.96

–

Antibody

Positive anti-SSA antibody, n (%)

118 (90.1)

–

Positive anti-SSB antibody, n (%)

61 (46.6)

–

Antinuclear antibody positive, n (%)

133 (88.1)

–

Serum marker

Total protein, g/L

72.6 (67.5–79.6)

74.5 (72.4–76.3)

Albumin, g/L

41.1 (36.7–44.4)

45.4 (44.4–46.8)

Globulin, g/L

31.8 (28–36.2)

28.5 (26.8–30.3)

Albumin/Glbumin

1.3 (1–1.5)

1.6 (1.5–1.7)

C-reactive protein, mg/L

2.6 (1.6–5.8)

–

Erythrocyte sedimentation rate, mm/h

51 (29–88)

–

Rheumatoid factor, IU/ ml

29.8 (20–100)

–

Complement fractions 4, mg/L

193 (147.5–230)

–

Complement fractions 3, mg/L

831 (723.5–953)

–

Immunoglobulins G, g/L

16.6 (13.4–20.8)

–

Immunoglobulins A, mg/L

3130 (2394–4000)

–

Immunoglobulins M, mg/L

1210 (849–1705)

–

White blood cell count, × 10⁹/L

5.4 (4.5–6.8)

5.7 (4.9–6.5)

Red blood cell count, × 10¹²/L

4.1 (3.8–4.5)

4.4 (4.2–4.7)

Haemoglobin, g/L

119.7 ± 19.1

130.3 ± 26

Neutrophil count, × 10⁹/L

3.4 (2.4–4.6)

3.1 (2.7–3.9)

Platelet count, × 10⁹/L

206.1 ± 84.8

246.5 ± 68